Liminatus Pharma Inc. Expands Board, Appoints Philip Lemons and Richard Baek as New Directors
Liminatus Pharma Inc. has expanded its board of directors to six members with the appointment of Philip Lemons and Richard Baek. Philip Lemons, 54, brings over two decades of experience in clinical research and development, having held leadership roles at various global research institutions and consulting firms. Richard Baek, 33, brings expertise in financial oversight and regulatory compliance, with a background in finance roles across multiple sectors. Both appointments are effective immediately.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-067444), on July 11, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。